



BeautyHealth's Hydrafacial Announces Partnership to Develop Breakthrough Exosome Booster

September 14, 2022

Co-Created with Organicell, the first-to-market booster will address aging and inflammation through regenerative technology

LONG BEACH, Calif.--(BUSINESS WIRE)--Sep. 14, 2022-- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial, today announced a collaboration with biotech company Organicell to co-create a first-to-market exosome booster that will address signs of aging and inflammation in the skin. The booster will leverage novel exosome technology based on regenerative medical therapies and, once developed, will be available as a customized treatment addition for Hydrafacial.

"We are excited to begin development with Organicell to co-create a potentially skin-changing Hydrafacial booster based on their breakthrough exosome technology," said BeautyHealth President and Chief Executive Officer Andrew Stanleick. "This partnership builds on our lineup of boosters and is the perfect example of the power of co-creation in our R&D model, which gives us access to the most novel technologies and formulas and translates them to market on an accelerated timetable."

Exosomes are small membrane vesicles, which are among the most productive and conducive to wound healing and countering inflammation. These benefits will help address signs of aging when delivered as a booster through Hydrafacial's exceptional delivery system.

The exosomes in Organicell's technology contain over 300 cytokines, chemokines and growth factors harvested under cGMP conditions that will allow Hydrafacial to put billions of exosomes in each booster vial. Within the booster, they will promote cellular communication, repair and regeneration to address signs of aging and inflammation like never before.

Organicell CEO Matt Sinnreich said, "Organicell is honored to pair our science team with Hydrafacial's formulators to help create a booster that not only pioneers a new technology but could potentially change the facial industry forever."

This collaboration marks a major advancement in Hydrafacial's booster strategy, which is centered around partnerships and co-creation. Today Hydrafacial has a lineup of 20 boosters, the majority co-created with fellow skincare brands such as Murad, ZO and JLo Beauty.

Hydrafacial's co-creation model can deliver a booster in under six months, a fraction of the time typically required to develop a full skincare line. This enables Hydrafacial to react rapidly to consumer trends, ensuring a constant flow of groundbreaking offerings that are directly addressing consumer needs.

Hydrafacial's new exosome booster will be available early next year.

About The Beauty Health Company

The Beauty Health Company is a global category-creating company focused on delivering beauty health experiences by reinventing our consumer's relationship with their skin, their bodies and their self-confidence. Our flagship brand, Hydrafacial™, created the category of hydradermabrasion by using a patented Vortex-Fusion Delivery System to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Hydrafacial™ provides a non-invasive and approachable experience with a powerful community of a/estheticians, consumers and partners, bridging aesthetics to beauty to democratize and personalize skincare solutions across ages, genders, skin tones, and skin types. Hydrafacial™ is available in over 90 countries with an install base of nearly 23,000 Delivery Systems providing millions of experiences to consumers each year. For more information, please visit www.beautyhealth.com.

About Organicell Regenerative Medicines, Inc.

Organicell Regenerative Medicine, Inc. (OTCQB:OCEL) is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and the provision of other related services. The Company's proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. To learn more, please visit <https://organicell.com>.

Forward-Looking Statements

Certain statements made in this press release are "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.

These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside The Beauty Health Company's control that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements.

Important factors, among others, that may affect actual results or outcomes include The Beauty Health Company's ability to manage growth; the possibility that The Beauty Health Company may be adversely affected by other economic, business, and/or competitive factors; the continued business relationship with Murad; the efficacy of the booster; and the impact of the continuing COVID-19 pandemic on the Company's business. The Beauty Health Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

HydraFacial Media: Marina Maher Communications | HydraFacial@hellommc.com

HydraFacial Investors: The One Nine Three Group | BeautyHealthIR@the193.com

Source: BeautyHealth